Angioplasty News and Research RSS Feed - Angioplasty News and Research

In angioplasty procedures, a balloon is fed through a catheter and used to prop open an artery that has become narrowed or blocked. In cases where stenting is appropriate, a stent mounted on a balloon is inserted and inflation of the balloon expands the stent against the blocked artery wall to hold the vessel open. The balloon is then deflated and the catheter is withdrawn. Stent treatment of arteries holds them open and improves blood flow to the heart. In cases where post-dilatation is needed, a high-pressure balloon is inflated inside a stent to help better place the stent against the vessel wall.
Dr. Mark Rasak recognized with Diamond Lifetime Achievement Award in the field of Medicine

Dr. Mark Rasak recognized with Diamond Lifetime Achievement Award in the field of Medicine

Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award in the field of Medicine as a result of his role as CEO of Cardiovascular Clinical Associates. [More]
Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium announces review in Journal of Cardiovascular Pharmacology finds gene therapy for subset of heart disease patients ‘highly warranted’

Cardium Therapeutics, an operating unit of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) has announced the publication of a review article in the Journal of Cardiovascular Pharmacology that concludes a gene therapy product promoting the growth of blood vessels is “highly warranted” to treat about 1 million U.S. heart-disease patients and 6 million more worldwide who are either ineligible or poor candidates for traditional angioplasty, stent placement or bypass surgery. [More]
Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Cardium reports positive results from Generx Ad5FGF-4 Phase 3 study for treatment of myocardial ischemia

Taxus Cardium Pharmaceuticals Group Inc. will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease. [More]
Study shows room for improvement in medical management of women with PAD

Study shows room for improvement in medical management of women with PAD

Women face greater limits on their lifestyle and have more severe symptoms as a result of peripheral artery disease (PAD), but minimally invasive procedures used to unclog arteries are just as successful as in men. [More]
Cardiac Catheterization Laboratory of Mount Sinai Heart receives highest "two-star" safety rating

Cardiac Catheterization Laboratory of Mount Sinai Heart receives highest "two-star" safety rating

The Cardiac Catheterization Laboratory of Mount Sinai Heart at The Mount Sinai Hospital has once again received the highest "two-star" safety rating from the New York State Department of Health for its percutaneous coronary interventions (PCI) overall and in non-emergency cases. [More]
Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death. [More]
Jersey Shore opens new CVICU to provide post-operative care for cardiac surgery patients

Jersey Shore opens new CVICU to provide post-operative care for cardiac surgery patients

Jersey Shore University Medical Center recently unveiled the new CardioVascular Intensive Care Unit (CVICU) - a twelve bed critical care unit providing post-operative care for cardiac surgery patients, including those who receive traditional open heart surgery and newer, complex interventional cardiovascular procedures. [More]
Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

Heparin proves effective than bivalirudin in patients receiving percutaneous coronary intervention after heart attack

In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. [More]
Corindus Vascular Robotics to showcase FDA-cleared CorPath System at ACC annual meeting

Corindus Vascular Robotics to showcase FDA-cleared CorPath System at ACC annual meeting

Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-cleared CorPath System at the upcoming American College of Cardiology annual meeting, March 29 – 31 in Washington, D.C. [More]
Concise analysis of the global pediatric interventional cardiology market

Concise analysis of the global pediatric interventional cardiology market

The report "Pediatric Interventional Cardiology Market by Congenital Heart Defect Closure Device [ASD, Ventricular Septal Defect, Patent Ductus Arteriosus, Left Atrial Appendage, Aortic Valve, Pulmonary Valve] & Procedures - Global Forecasts to 2018", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, APAC, and the Rest of the World. [More]
CSI's new Diamondback Peripheral 60cm systems receive FDA clearance for PAD treatment

CSI's new Diamondback Peripheral 60cm systems receive FDA clearance for PAD treatment

Cardiovascular Systems, Inc., announced today it has received FDA clearance of its new Diamondback 360 60cm Peripheral Orbital Atherectomy Systems (OAS) for the treatment of peripheral arterial disease (PAD). [More]
Report highlights benefits of different access approach to treat uterine fibroids

Report highlights benefits of different access approach to treat uterine fibroids

Interventional radiologists have devised a new way to access a woman's fibroids-by flipping her wrist and treating via an arm not groin artery-to nonsurgically shrink noncancerous growths in the muscular wall of the uterus. Researchers found this to be less painful and traumatic for women, allowing them to immediately sit up and move after uterine fibroid embolization (UFE)-with no overnight stay, according to a March article in the Society of Interventional Radiology's flagship publication, the Journal of Vascular and Interventional Radiology. [More]
Long-term risks of deep vein thrombosis

Long-term risks of deep vein thrombosis

Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March's DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT. [More]
Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator. [More]
Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Zilver PTX randomized trial of paclitaxel-eluting stents for femoropopliteal disease demonstrates superior results

Four-year results of the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease continue to demonstrate consistent, superior results when compared to bare metal stents (BMS) and percutaneous transluminal angioplasty (PTA) in terms of primary patency, restenosis reduction and revascularization rates. [More]
New technology to enhance angioplasty with added precision, accuracy and less radiation exposure

New technology to enhance angioplasty with added precision, accuracy and less radiation exposure

Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty. [More]
Researchers evaluate trends in cause-specific long-term mortality post PCI

Researchers evaluate trends in cause-specific long-term mortality post PCI

More people who have known coronary heart disease die from other causes — such as cancer, and lung and neurological diseases — than heart disease, compared with 20 years ago, according to a Mayo Clinic study published online today in Circulation, an American Heart Association journal. [More]

New method to build tiny degradable 'medicine factories' inside the body

A factory built of gel does not sound very durable. But the new type of micro-factories invented by researchers at Aarhus University do not have to last. [More]
Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

Bioengineer receives $1.4M grant to create nanoparticle system to shore up arterial walls

A UT Arlington bioengineer has received a four-year, $1.4 million National Institutes of Health grant to create a nanoparticle system to shore up arterial walls following angioplasty and stenting procedures to treat coronary arterial disease. [More]
Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott. [More]